Business Wire

ViacomCBS Appoints Raffaele Annecchino President and CEO, ViacomCBS Networks International

10.12.2020 17:00:00 EET | Business Wire | Press release

Share

ViacomCBS, Inc. (NASDAQ: VIAC, VIACA) today announced that Raffaele Annecchino has been appointed President and CEO of ViacomCBS Networks International (VCNI), effective immediately. He succeeds David Lynn, who is stepping down and will depart the company following a transition period.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005567/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ViacomCBS has appointed Raffaele Annecchino President and CEO, ViacomCBS Networks International (VCNI) (Photo: ViacomCBS)

In his new role, Annecchino will oversee all of ViacomCBS’s media networks and related businesses outside the U.S. As part of this, he will be responsible for a portfolio of pay-TV entertainment brands and broadcast networks across six continents – including Channel 5 in the UK, Telefe in Argentina, Network 10 in Australia and Colors in India through a joint venture with Viacom18 – and work closely with ViacomCBS’s global streaming organization to help guide the continued international rollout of Pluto TV and the launch of Paramount+ in 2021. He will report to Bob Bakish, President and CEO, ViacomCBS.

“Raffaele is an entrepreneurial, results-oriented leader with a proven ability to transform businesses and drive growth across diverse markets,” said Bakish. “In recent years, Raffaele has taken on increased responsibility, demonstrating strategic and operational expertise that extends across a wide variety of geographies and platforms. His experience in expanding ViacomCBS’s international footprint, forging key partnerships and accelerating our push into mobile and digital platforms will be critical to building on our leadership positions across Europe, Latin America and Asia and realizing our global ambitions.”

Bakish added, “I want to extend my deepest thanks to David for his many contributions over the past two decades, from integrating the international portfolios of CBS and Viacom to overseeing the launch of Viacom International Studios, including the acquisition of Ananey and repositioning the division to enable the continued expansion of our global streaming offerings. I’m grateful for his dedication and leadership and wish him the best as he starts this next chapter.”

“It’s an honor to step into this role and help continue ViacomCBS’s strong momentum around the world,” said Annecchino. “We have an exciting opportunity to broaden the company’s reach through new, innovative distribution channels and partnerships, and I look forward to working with Bob and the rest of the team to execute against our growth initiatives.”

Over the course of his 23-year tenure, Annecchino has held a number of positions across ViacomCBS Networks International, formerly Viacom International Media Networks (VIMN). Most recently, he served as President of ViacomCBS Networks Europe, Middle East, Africa and Asia (EMEAA), during which time he oversaw operations across a range of markets and led and coordinated VCNI’s mobile strategy globally. Among his achievements were the launch and acquisition of free-to-air channels in the key markets of Italy, Spain and Germany, and the creation of a new business unit in September 2020 to help drive ViacomCBS’s digital businesses across the EMEAA region, including capturing opportunities across free and pay streaming, advanced advertising and ViacomCBS Digital Studios International. Annecchino also led the expansion of Pluto TV in Europe with the recent successful launch of the service in Spain and the upcoming roll out in France and Italy in 2021.

Prior to joining MTV Networks International in 1997, Annecchino held positions at Turner International, Cartoon Network and CNN. He holds a Bachelor of Economics from the European Business School, London, UK, and an Executive MBA from the Instituto de Empresa International, Madrid, Spain. He completed the CTAM U Executive Management Program at Harvard Business School in 2016 and the CTAM Europe Executive Management Program at INSEAD in 2017.

Lynn commented, “It’s been an honor and a privilege to spend the greatest part of my career at ViacomCBS. From my early days at Comedy Central and Nickelodeon to more recently managing teams across our global portfolio, I’ve benefitted from working with the most dynamic, talented team in the industry – who in this most challenging year succeeded in transforming the business for the next important phase of growth.”

As President and CEO of VCNI and, before that, VIMN, Lynn was responsible for numerous strategic growth initiatives to diversify the company’s international business, which led to a significant increase in the company’s digital advertising and subscription revenues, among other achievements. As part of this, Lynn oversaw the launch of Viacom International Studios and the international rollout of Pluto TV and Noggin. Previously, he served as President of VIMN UK, Northern and Eastern Europe, where he oversaw Viacom’s global distribution strategy and led the acquisition of Channel 5 Broadcasting and its integration into Viacom. Before that, he was SVP, Managing Director, for Nickelodeon UK, where he strengthened its position in one of the UK’s most competitive viewing demographics, launching Nick Jr. and kick-starting its digital strategy.

About ViacomCBS

ViacomCBS (NASDAQ: VIAC; VIACA) is a leading global media and entertainment company that creates premium content and experiences for audiences worldwide. Driven by iconic consumer brands, its portfolio includes CBS, Showtime Networks, Paramount Pictures, Nickelodeon, MTV, Comedy Central, BET, CBS All Access, Pluto TV and Simon & Schuster, among others. The company delivers the largest share of the U.S. television audience and boasts one of the industry’s most important and extensive libraries of TV and film titles. In addition to offering innovative streaming services and digital video products, ViacomCBS provides powerful capabilities in production, distribution and advertising solutions for partners on five continents.

For more information about ViacomCBS, please visit www.viacomcbs.com and follow @ViacomCBS on social platforms.

ViacomCBS Networks International

ViacomCBS Networks International, a unit of ViacomCBS Inc. (NASDAQ: VIAC), comprises many of the world’s most iconic entertainment brands, including Network 10, Channel 5, Telefe, Viacom 18, ViacomCBS International Studios, Nickelodeon, MTV, Comedy Central, BET, Paramount Network and Pluto TV. In addition to offering innovative streaming services and digital video products, ViacomCBS Networks International provides powerful capabilities in production, distribution and advertising solutions for partners on five continents and across more than 180 countries.

VIAC-IR

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Kate Laverge
Senior Vice President, Communications, ViacomCBS Networks International
kate.laverge@viacom.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye